Gilead’s Kite, Arcellx Expand BCMA CAR-T Partnership Into Lymphomas

The amendment to a December 2022 deal expands their myeloma CAR-T partnership and will see development of CART-ddBCMA in lymphomas, where research indicates anti-BCMA therapy has activity.

Gilead's Kite and Arcellx announced an expansion to their CAR-T development partnership. • Source: Shutterstock

The expansion of the partnership between Gilead Sciences, Inc.’s Kite Pharma division and Arcellx, Inc. to include an additional multiple myeloma program as well as lymphomas brings Arcellx additional cash while also providing a potential competitive advantage to the BCMA-directed CAR-T cell therapy program that is the partnership’s focus.

The two companies announced the expanded deal on 15 November, with Kite exercising an option for Arcellx’s ARC-SparX program ACLX-001...

More from Deals

More from Business